Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1554 Trials   75234 News 


«12...7576777879808182838485...858859»
  • ||||||||||  ivabradine / Generic mfg.
    Review, Journal:  Drug Therapy for Acute and Chronic Heart Failure with Preserved Ejection Fraction with Hypertension: A State-of-the-Art Review. (Pubmed Central) -  Apr 4, 2024   
    We also explored emerging drug therapies for HFpEF, such as sodium-glucose co-transporter 2 (SGLT2) inhibitors, angiotensin receptor-neprilysin inhibitor (ARNI), soluble guanylate cyclase (sGC) stimulators, novel MRAs, and ivabradine...Furthermore, long-term studies are essential to assess the durability and sustained benefits of emerging drug therapies. Identification of novel targets and mechanisms underlying HFpEF pathophysiology will pave the way for innovative drug development approaches in the management of HFpEF with concurrent hypertension.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Sclerotic bone: a sign of bone reaction in patients with medication related osteonecrosis of the jaw. (Pubmed Central) -  Apr 4, 2024   
    Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse reaction associated with antiresorptive drugs such as bisphosphonates and denosumab...The pre and postoperative density showed no significant correlation to healing behaviour. The focus of the modelling osteotomy in surgical treatment of mature MRONJ lesions should be predominantly on the parts that appear necrotic and less dense in the panoramic radiograph as sclerotic areas might be an expression of bone reaction.
  • ||||||||||  Vectibix (panitumumab) / Amgen
    Trial primary completion date:  Phase II Panitumumab-IRDye800 in Head & Neck Cancer (clinicaltrials.gov) -  Apr 4, 2024   
    P2,  N=25, Recruiting, 
    The focus of the modelling osteotomy in surgical treatment of mature MRONJ lesions should be predominantly on the parts that appear necrotic and less dense in the panoramic radiograph as sclerotic areas might be an expression of bone reaction. Trial primary completion date: Dec 2025 --> Dec 2026
  • ||||||||||  Humira (adalimumab) / AbbVie
    Journal:  Adalimumab in the management of psoriasis and psoriatic arthritis: Results from a Delphi investigation. (Pubmed Central) -  Apr 4, 2024   
    Results from this Delphi study clearly show an overall consensus on the use of adalimumab in the management of PsO and PsA, particularly as first-choice for specific subpopulations (uveitis, IBD, hidradenitis suppurativa). Considering the cost-effectiveness of biosimilars within Italy, adalimumab may represent an effective and safe first-line treatment for patients with moderate-to-severe PsO or PsA, and a valid choice for switching after failure.
  • ||||||||||  Vectibix (panitumumab) / Amgen, Lumakras (sotorasib) / Amgen
    Journal, Metastases:  Twelve-month progression-free survival with sotorasib and panitumumab in KRAS G12C mutant metastatic colorectal cancer. (Pubmed Central) -  Apr 4, 2024   
    Promising inhibitors such as sotorasib and adagrasib targeting KRASG12C mutations have demonstrated efficacy...Treatment with FOLFIRINOX and bevacizumab, and later FOLFIRI and bevacizumab, with surgeries and local interventions resulted in partial responses...This case highlights the remarkable outcome of a heavily treated KRAS G12C mutant mCRC patient. The combination of sotorasib and panitumumab, along with multidisciplinary approaches including surgery and local interventions, played an important role in our patient's survival.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Trial completion, Enrollment change, Trial completion date:  Blina-CELL: Blinatumomab Followed by High-dose Chemotherapy for Ph-negative Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) -  Apr 4, 2024   
    P2,  N=27, Completed, 
    The combination of sotorasib and panitumumab, along with multidisciplinary approaches including surgery and local interventions, played an important role in our patient's survival. Active, not recruiting --> Completed | N=45 --> 27 | Trial completion date: Jul 2024 --> Feb 2024
  • ||||||||||  ivabradine / Generic mfg.
    Journal:  Screening effects of HCN channel blockers on sleep/wake behavior in zebrafish. (Pubmed Central) -  Apr 3, 2024   
    Results of interest included shorter latency to daytime sleep at 0.1??M dose of Ivabradine (ANOVA, p: 0.02), moderate reduction in average activity at 30 ?M dose of Zatebradine Hydrochloride (ANOVA, p: 0.024) in daytime, and increased nighttime sleep at 4.5 ?M dose of ZD7288 (ANOVA, p: 0.036). Taken together, shorter latency to daytime sleep, decrease in daytime activity and increased nighttime sleep indicate that different HCN channel antagonists affected different parameters of sleep and activity.
  • ||||||||||  Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
    Journal:  Short versus long-acting erythropoiesis-stimulating agents for anemia management in Egyptian hemodialysis patients. (Pubmed Central) -  Apr 3, 2024   
    P
    Taken together, shorter latency to daytime sleep, decrease in daytime activity and increased nighttime sleep indicate that different HCN channel antagonists affected different parameters of sleep and activity. In hemodialysis Egyptian patients, Aranesp with extended dosing intervals proved to be more effective in achieving target Hb with comparable adverse effect profiles, a substantial cost-saving strategy, and offered time-saving advantages for medical staff workload compared to Eprex.
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Journal:  Development of a novel humanized anti-TSLP monoclonal antibody HZ-1127 with anti-allergic diseases and cancer potential. (Pubmed Central) -  Apr 3, 2024   
    Furthermore, HZ-1127 dramatically inhibits TSLP-dependent STAT5 activation and is more potent than Tezepelumab, which is an FDA-approved humanized mAb against TSLP for severe asthma treatment in inhibiting TSLP-induced CCL17 and CCL22 chemokines secretion in human peripheral blood mononuclear cells. Our pre-clinical study demonstrates that HZ-1127 may serve as a potential therapeutic agent for allergic diseases and cancer.
  • ||||||||||  omecamtiv mecarbil (AMG 423) / Amgen, Servier
    Review, Journal:  Omecamtiv Mecarbil in the treatment of heart failure: the past, the present, and the future. (Pubmed Central) -  Apr 3, 2024   
    These of no doubt make the present article the most systemic and informative one among the existing literature. Overall, by offering new mechanistic insights and therapeutic possibilities, OM has carved a significant niche in the treatment of heart failure, making it a compelling subject of study.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Giant Cell Tumor of Mandible : A Case Report. (Pubmed Central) -  Apr 3, 2024   
    After exclusion of distant metastasis by F-18 FDG PET scan, she underwent en-bloc resection of the tumor with free fibula flap reconstruction. During 6 months of follow up visit patient had no recurrence.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Recurrent Giant Cell Tumor of Sphenoid Bone: A Rare Finding. (Pubmed Central) -  Apr 3, 2024   
    Here, we describe a case of recurrent giant cell tumor of sphenoid bone in a young male, who underwent surgical resection twice, after which he was advised adjuvant radiotherapy and denosumab. The patient did not take radiotherapy.
  • ||||||||||  dazodalibep (HZN-4920) / Amgen
    Enrollment open:  HZNP-DAZ-303: A Safety and Efficacy Study of Dazodalibep in Participants With Sj (clinicaltrials.gov) -  Apr 2, 2024   
    P3,  N=435, Recruiting, 
    Recruiting --> Completed | N=225 --> 107 | Trial completion date: Nov 2023 --> Mar 2024 | Trial primary completion date: Nov 2023 --> Mar 2024 Not yet recruiting --> Recruiting
  • ||||||||||  Neulasta (pegfilgrastim) / Roche, Rituxan (rituximab) / Roche
    Journal:  Patient Out-of-Pocket Costs for Biologic Drugs After Biosimilar Competition. (Pubmed Central) -  Apr 2, 2024   
    This cohort study used a national commercial claims database (Optum Clinformatics Data Mart) to identify outpatient claims for 1 of 7 clinician-administered biologics (filgrastim, infliximab, pegfilgrastim, epoetin alfa, bevacizumab, rituximab, and trastuzumab) from January 2009 through March 2022...Findings varied by drug. Findings of this cohort study suggest that biosimilar competition was not consistently associated with lower OOP costs for commercially insured outpatients, highlighting the need for targeted policy interventions to ensure that the savings generated from biosimilar competition translate into increased affordability for patients who need biologics.
  • ||||||||||  Prolia (denosumab) / Amgen, Tagrisso (osimertinib) / AstraZeneca
    Retrospective data, Journal:  Assessing EGFR-mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategy. (Pubmed Central) -  Apr 2, 2024   
    The presence of BoM is a negative prognostic factor for NSCLC patients with an EGFR mutation, possibly due to the presence of extrathoracic metastases. However, adding AAT and denosumab, along with sequential osimertinib, to the treatment regimen for patients with BoM can improve survival outcomes.
  • ||||||||||  Stivarga (regorafenib) / Bayer
    Targeting inflammasome activation by sorafenib/regorafenib as strategy to enhance efficacy in hepatocellular carcinoma therapy (Poster Area) -  Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1534;    
    This study unveils the inflammasome pathway as a promising and actionable therapeutic target to increase the efficacy of sorafenib/regorafenib therapy for HCC. The identified inflammasome signature in HCC and surrounding tissue associates with TKI administration, suggesting that targeting inflammasome activation, particularly in male patients, may overcome sorafenib/regorafenib resistance and enhance the overall efficacy of TKI treatments in HCC.
  • ||||||||||  Tecentriq (atezolizumab) / Roche, Mvasi (bevacizumab-awwb) / Daiichi Sankyo, Amgen, AbbVie
    Liver cancer in ovo models for preclinical testing (Poster Area) -  Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1520;    
    Our results reveal mitochondrial damage and the mtDNA-cGas-STING axis as compelling targets in antitumor efficacy with a potential role in immunological responses. Treatments with atezolizumab (anti-PD-L1, TECENTRIQ
  • ||||||||||  Stivarga (regorafenib) / Bayer
    Role of the splicing factor PCBP2 in cholangiocarcinoma malignancy and chemoresistance (Poster Area) -  Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1516;    
    MTT assay was performed to determine the effect on cell viability of anti-tumor drugs (cisplatin, oxaliplatin, gemcitabine, 5-FU, sorafenib, and regorafenib)... PCBP2 may act as a relevant factor in regulating cell migration and proliferation in CCA and, therefore, a potential target to be considered in developing novel strategies to treat this cancer.